Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one drug fit all' model for patients that display same pathological conditions. However, CRC is a very heterogenous set of malignancy that does not support for above criteria. Each subtype displays different pathological and genetic signatures. Based on these features, therapeutic stratification for individual patients may be designed, which may ultimately lead to improved therapeutic outcomes. In this comprehensive review, we have attempted to briefly outline major CRC pathways. A detailed overview of molecular subtypes and their clinical significance has been discussed. Present and future methods, governing CRC subtyping in the era of personalized therapy with a special emphasis on CMS subtypes of CRC has been reviewed. Together, discovery and validation of new CRC patient stratification methods, screening for novel therapeutic targets, and enhanced diagnosis of CRC may improve the treatment outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 1×
“On the basis of above positive therapeutic response in 2017 FDA initialize the approval of pembrolizumab as a second or higher line drug choice for wider coverage of patients with un resectable, MSI H solid tumors.(60,94,95) Another key immune check point blocker nivolumab was analyzed with dMMR/MSI H in an open label…”
BackgroundNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“The efficiency of immune checkpoint blockade in advanced dMMR tumors was achieved as expected in 53% and complete response in (21%) of the patients.(61)”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 1×
“MSI high tumors display worse prognosis in sporadic tumors while lynch syndrome appears to have better prognosis.(54) It was reported that dMMR tumors have better prognosis than MSS.”
BackgroundSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Vast amount of data generated from various types of omics studies has been successfully correlated to demographic and phenotypic characteristics and associated with various molecular subtypes.(52) Recently, Sveen A et al (2018) established a preclinical model to explore targetable cancer cell dependencies in an in-vit…”
BackgroundOverman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 1×
“In CheckMate142 trial 119 mCRC (MSI H) patients having received nivolumab plus ipilimumab showed a better ORR (55%), DCR for more than 12 weeks (80%), 12 months PFS (71%) and corresponding OS was 85%.(93,96) The immune check pint blockers have the potential to prevent the disease progression, but all above and availab…”
BackgroundMarisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176 · cited 1×
“On the basis of above positive therapeutic response in 2017 FDA initialize the approval of pembrolizumab as a second or higher line drug choice for wider coverage of patients with un resectable, MSI H solid tumors.(60,94,95) Another key immune check point blocker nivolumab was analyzed with dMMR/MSI H in an open label…”
BackgroundCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 1×
“23) in comparison to FOLFIRI þ bevacizumab therapy.(87) For the BRAF mutant with MSI-H patients, there is still an absence of defined criteria whether immunotherapy or BRAF inhibitor along with other drugs may improve the therapeutic outcome and propose a better therapeutic approach.”
ResultRecurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
Ligtenberg, M. J. L., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., Lee, T. Y. H., Bodmer, D., Hoenselaar, E., Hendriks-Cornelissen, S. J. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.283 · Cited by 818 · cited 1×
“Is described as one of the cause of Lynch syndrome.(12)”
BackgroundDe Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 2×
“Further to this, mutational status of KRAS (exon2), BRAF (V600E) and PIK3CA shows the path for anti-EGFR therapy of mCRCs.(4,5) Since molecular events play a crucial role in prognosis and deciding the therapy regimen it becomes essential to identify and characterize a molecular subtype of an individual tumor.”
BackgroundMechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · cited 1×
“Further to this, mutational status of KRAS (exon2), BRAF (V600E) and PIK3CA shows the path for anti-EGFR therapy of mCRCs.(4,5) Since molecular events play a crucial role in prognosis and deciding the therapy regimen it becomes essential to identify and characterize a molecular subtype of an individual tumor.”
BackgroundSveen, A., Bruun, J., Eide, P. W., Eilertsen, I. A., Ramirez, L., Murumägi, A., Arjama, M., Danielsen, S. A., Kryeziu, K., Elez, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1234 · Cited by 256 · cited 1×
“Interestingly CMS4 subtype displays a distinct chemoresistance against a combination of 5-FU and luminespib drugs.(53) Molecular subtype alone does not appear to be very helpful in targeted therapy due to lack of integration of transcriptomic, genomic and proteomic data into a reproducible and reliable cluster that ma…”
BackgroundGatalica, Z., Vranic, S., Xiu, J., Swensen, J., & Reddy, S. (2016) · Familial Cancer · doi:10.1007/s10689-016-9884-6 · Cited by 141 · cited 1×
“It is prominently reported in various studies that approximately 15% of all CRCs have high frequency of MSI due to germline mutations in mismatch repair (MMR) system or somatic inactivation by promoter hypermethylation of MLH1 gene.(10) HNPCC (Hereditary Non polyposis Colorectal cancer) or Lynch syndrome (~3%) is an i…”
Background
Research works printed but not linked: 79
- Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J Clin, 68, 394
- Nakayama, 2013, Current options for the diagnosis, staging and therapeutic management of colorectal cancer, Gastrointest Tumours, 1, 25, 10.1159/000354995 · DOI
- Mundade, 2014, Genetic pathways, prevention, and treatment of sporadic colorectal cancer, Oncoscience, 1, 400, 10.18632/oncoscience.59 · DOI
- Worthley, 2007, Colorectal carcinogenesis: road maps to cancer, World J Gastroenterol, 13, e3784, 10.3748/wjg.v13.i28.3784 · DOI
- Pino, 2010, The chromosomal instability pathway IN colon cancer, Gastroenterology, 138, 2059, 10.1053/j.gastro.2009.12.065 · DOI · Paper page
- Esteller, 2001, A gene hypermethylation profile of human cancer, Cancer Res, 61, 3225
- Hewish, 2010, Mismatch repair deficient colorectal cancer in the era of personalized treatment, Nat Rev Clin Oncol, 7, 197, 10.1038/nrclinonc.2010.18 · DOI · Paper page
- Migliore, 2011, Genetics, cytogenetics, and epigenetics of colorectal cancer, J Biomed Biotechnol, 2011, e792362
- Weisenberger, 2015, Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history, Cancer Epidemiol Biomark Prev, 24, 512, 10.1158/1055-9965.EPI-14-1161 · DOI
- Curtin, 2011, CpG island methylation in colorectal cancer: past, present and future, Pathol Res Int, 2011, 10.4061/2011/902674 · DOI · Paper page
- Ogino, 2007, Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample, J Mol Diagn, 9, 305, 10.2353/jmoldx.2007.060170 · DOI · Paper page
- Toyota, 2000, Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype, Proc Natl Acad Sci USA, 97, 710, 10.1073/pnas.97.2.710 · DOI · Paper page
- Weisenberger, 2006, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat Genet, 38, 787, 10.1038/ng1834 · DOI · Paper page
- Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci U S A, 96, 8681, 10.1073/pnas.96.15.8681 · DOI · Paper page
- Shen, 2007, Methods of DNA methylation analysis, Curr Opin Clin Nutr Metab Care, 10, 576
- Yagi, 2010, Three DNA methylation epigenotypes in human colorectal cancer, Clin Cancer Res, 16, 21, 10.1158/1078-0432.CCR-09-2006 · DOI · Paper page
- Sjöblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427 · DOI · Paper page
- Leary, 2008, Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers, Proc Natl Acad Sci USA, 105, 16224, 10.1073/pnas.0808041105 · DOI · Paper page
- Jass, 2007, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 50, 113, 10.1111/j.1365-2559.2006.02549.x · DOI · Paper page
- Lee, 2008, Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation, Pathol Int, 58, 104, 10.1111/j.1440-1827.2007.02197.x · DOI · Paper page
- Nosho, 2008, PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations, Neoplasia, 10, 534, 10.1593/neo.08336 · DOI · Paper page
- Ward, 2003, Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability, J Clin Oncol, 21, 3729, 10.1200/JCO.2003.03.123 · DOI · Paper page
- Ogino, 2008, Molecular classification and correlates in colorectal cancer, J Mol Diagn, 10, 13, 10.2353/jmoldx.2008.070082 · DOI · Paper page
- Saltz, 2004, Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803), J Clin Orthod, 22, e3500
- Shiovitz, 2014, CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage 3 colon cancer, Gastroenterology, 147, 637, 10.1053/j.gastro.2014.05.009 · DOI · Paper page
- Han, 2013, Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer, Int J Cancer, 132, 2209, 10.1002/ijc.27888 · DOI
- Sinicrope, 2016, Molecular biomarkers in the personalized treatment of colorectal cancer, Clin Gastroenterol Hepatol, 14, 651, 10.1016/j.cgh.2016.02.008 · DOI · Paper page
- Ogino, 2006, CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations, J Mol Diagn, 8, 582, 10.2353/jmoldx.2006.060082 · DOI · Paper page
- Ogino, 2007, Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype, Hum Pathol, 38, 842, 10.1016/j.humpath.2006.11.018 · DOI
- Goel, 2007, The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer, Gastroenterology, 132, 127, 10.1053/j.gastro.2006.09.018 · DOI · Paper page
- Samowitz, 2005, Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer, Gastroenterology, 129, 837, 10.1053/j.gastro.2005.06.020 · DOI · Paper page
- Ogino, 2007, Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer, Gut, 56, 1564, 10.1136/gut.2007.119750 · DOI
- Ogino, 2007, 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high, BMC Canc, 7, e72, 10.1186/1471-2407-7-72 · DOI
- Van der Flier, 2007, The intestinal Wnt/TCF signature, Gastroenterology, 132, 628, 10.1053/j.gastro.2006.08.039 · DOI · Paper page
- Khambata-Ford, 2007, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 3230, 10.1200/JCO.2006.10.5437 · DOI · Paper page
- Sadanandam, 2013, A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, 19, 619, 10.1038/nm.3175 · DOI · Paper page
- Jorissen, 2008, DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers, Clin Cancer Res, 14, 8061, 10.1158/1078-0432.CCR-08-1431 · DOI · Paper page
- Jorissen, 2009, Metastasis-associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer, Clin Cancer Res, 15, 7642, 10.1158/1078-0432.CCR-09-1431 · DOI · Paper page
- Roepman, 2014, Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, 134, 552, 10.1002/ijc.28387 · DOI · Paper page
- Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
- Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
- Sinicrope, 2013, Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy, J Clin Oncol, 31, 3664, 10.1200/JCO.2013.48.9591 · DOI · Paper page
- Ogino, 2009, CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer, Gut, 58, 90, 10.1136/gut.2008.155473 · DOI · Paper page
- Deschoolmeester, 2011, Immune cells in colorectal cancer: prognostic relevance and role of MSI, Canc Microenviron, 4, 377, 10.1007/s12307-011-0068-5 · DOI
- De Smedt, 2015, Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis, Br J Canc, 113, 500, 10.1038/bjc.2015.213 · DOI
- Park, 2016, Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment, Br J Canc, 114, 562, 10.1038/bjc.2016.17 · DOI
- Singh, 2015, Immune checkpoints and immunotherapy for colorectal cancer, Gastroenterol Rep (Oxf), 3, 289
- Teng, 2015, IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, Nat Med, 21, 719, 10.1038/nm.3895 · DOI · Paper page
- Najdi, 2011, Wnt signaling and colon carcinogenesis: beyond APC, J Carcinog, 10, e5, 10.4103/1477-3163.78111 · DOI · Paper page
- Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br J Canc, 108, 1757, 10.1038/bjc.2013.118 · DOI · Paper page
- Ghidini, 2016, KRAS mutation in lung metastases from colorectal cancer: prognostic implications, Cancer Med, 5, 256, 10.1002/cam4.592 · DOI
- Hagland, 2013, Molecular pathways and cellular metabolism in colorectal cancer, Dig Surg, 30, 12, 10.1159/000347166 · DOI
- Fang, 2016, Advances in glucose metabolism research in colorectal cancer, Biomed Rep, 5, 289, 10.3892/br.2016.719 · DOI
- Chen, 2015, Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism, OncoTarget, 6, 24148, 10.18632/oncotarget.4376 · DOI
- Chen, 2018, Propofol elicits autophagy via endoplasmic reticulum stress and calcium exchange in C2C12 myoblast cell line, PLoS One, 13, e0197934, 10.1371/journal.pone.0197934 · DOI
- Satoh, 2017, Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC, Proc Natl Acad Sci, 114, E7697, 10.1073/pnas.1710366114 · DOI · Paper page
- Park, 2014, The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer, Ann Oncol, 25, 644, 10.1093/annonc/mdt593 · DOI · Paper page
- Staudacher, 2017, Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer, Sci Rep, 7, e5569, 10.1038/s41598-017-05907-8 · DOI · Paper page
- de Gramont, 2016, Novel TGF-β inhibitors ready for prime time in onco-immunology, OncoImmunology, 6, e1257453, 10.1080/2162402X.2016.1257453 · DOI · Paper page
- Sadanandam, 2014, Reconciliation of classification systems defining molecular subtypes of colorectal cancer, Cell Cycle, 13, 353, 10.4161/cc.27769 · DOI · Paper page
- Garza-Treviño, 2015, Understanding the colon cancer stem cells and perspectives on treatment, Cancer Cell Int, 15, e2, 10.1186/s12935-015-0163-7 · DOI
- Pogue-Geile, 2016, Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: results from NRG Oncology/NSABP C-07, J Clin Orthod, 34, e3510
- Qiu, 2018, Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer, OncoTargets Ther, 11, 465, 10.2147/OTT.S149110 · DOI
- Graham, 2016, Molecular subtypes and personalized therapy in metastatic colorectal cancer, Curr Colorectal Canc Rep, 12, 141
- Rodriguez-Salas, 2017, Clinical relevance of colorectal cancer molecular subtypes, Crit Rev Oncol Hematol, 109, 9, 10.1016/j.critrevonc.2016.11.007 · DOI
- Dorard, 2011, Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis, Nat Med, 17, 1283, 10.1038/nm.2457 · DOI · Paper page
- Koenig, 2018, Microsatellite instability and adjuvant chemotherapy in stage II colon cancer, J Clin Orthod, 36, e767
- Douillard, 2014, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Canc, 110, 55, 10.1038/bjc.2013.721 · DOI · Paper page
- Ciardiello, 2016, Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX, Ann Oncol, 27, 1055, 10.1093/annonc/mdw136 · DOI
- Peeters, 2015, Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer, Clin Cancer Res, 21, 5469, 10.1158/1078-0432.CCR-15-0526 · DOI · Paper page
- Rowland, 2015, Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer, Br J Canc, 112, 1888, 10.1038/bjc.2015.173 · DOI · Paper page
- Kopetz, 2017, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406), J Clin Orthod, 35, e520
- Overman, 2016, Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results, J Clin Orthod, 34, e3501
- Lemery, 2017, First FDA approval agnostic of cancer site - when a biomarker defines the indication, N Engl J Med, 377, 1409, 10.1056/NEJMp1709968 · DOI · Paper page
- Siravegna, 2017, Integrating liquid biopsies into the management of cancer, Nat Rev Clin Oncol, 14, 531, 10.1038/nrclinonc.2017.14 · DOI · Paper page
- Ogino, 2018, Immunoscore for (colorectal) cancer precision medicine, The Lancet, 391, 2084, 10.1016/S0140-6736(18)30953-X · DOI
- Martin, 2013, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients, Br J Canc, 108, 668, 10.1038/bjc.2013.4 · DOI · Paper page
- Laurent-Puig, 2016, ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8), Ann Oncol, 27, vi149
- Madan, 2016, Wnt addiction of genetically defined cancers reversed by PORCN inhibition, Oncogene, 35, 2197, 10.1038/onc.2015.280 · DOI · Paper page
Cited by
High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer
Oliveira, M. F. D., Romero, J. P., Chung, M., Williams, S. R., Gottscho, A. D., Gupta, A., Pilipauskas, S. E., Mohabbat, S., Raman, N., Sukovich, D. J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02193-3 · Cited by 321
Bilal, M., Raza, S. E. A., Azam, A., Graham, S., Ilyas, M., Cree, I. A., Snead, D., Minhas, F., & Rajpoot, N. M. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00180-1 · Cited by 299
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
Survival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment
Zhang, C., Xu, J., Tang, R., Yang, J., Wang, W., Yu, X., & Shi, S. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01514-5 · Cited by 148
Metadata
- Authors
- Singh, M. P., Rai, S., Pandey, A., Singh, N. K., & Srivastava, S.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 8
- Issue
- 2
- Pages
- 133-145
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W2985795188
- Cited by
- 146
- References
- 23
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Department of Biotechnology, Government of West Bengal
- Department of Biotechnology, Ministry of Science and Technology, India (6242-P103/RGCB/PMD/DBT/SMSV/2015)
- Council of Scientific and Industrial Research, India
- Ministry of Education, India
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.